Abiopharma

🔍 RA CAPITAL MANAGEMENT, L.P. (Executive)

Company: Werewolf Therapeutics, Inc. (HOWL)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Sold 351,514 shares of Common Stock at $0.71 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,885,968.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 25,012 shares of Common Stock at $0.71 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 418,813.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 81,678 shares of Common Stock at $0.67 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,804,290.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 5,812 shares of Common Stock at $0.67 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 413,001.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 94,432 shares of Common Stock at $0.64 per share (Direct)
  Date: 2026-05-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,709,858.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Sold 6,719 shares of Common Stock at $0.64 per share (Direct)
  Date: 2026-05-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 406,282.00 | transaction_form_type: 4 | Footnotes: F6, F3

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
• F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
• F4: Held directly by Nexus Fund II.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.71 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.